Cell therapies constitute the largest number of agents in development in immuno-oncology (Nat. Rev. Drug Discov. 18, 899–900; 2019). Here, we provide an update on the pipeline and clinical trials of cancer cell therapies. We also compare the current landscape (with a March 2020 data cut-off point) with our previous update from March 2019 (Nat. Rev. Drug Discov. 18, 821–822; 2019).

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD